AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20847105
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 1,000 μg/day
Trial: 20847105
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2,000 μg/day
Trial: 20847105
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation in participants with low serum folate (<4.5 ng/mL)
Trial: 18665698
Drug: Psychoeducational Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational Supportive Treatment (PE-SUP)
Trial: 10661332
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (ifosfamide, etoposide, high-dose methotrexate, cisplatin, cytarabine)
Trial: 10661332
Drug: Immediate postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate postoperative radiotherapy with vincristine followed by maintenance chemotherapy (cisplatin, CCNU, vincristine)
Trial: 10661332
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (arm I)
Trial: 20350693
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous diuretics (IV)
Trial: 20350693
Drug: Bolus diuretics
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus diuretics
Trial: 17967134
Drug: Calcium 1
RxNorm normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1 g/d and vitamin D 800 UI/d
Trial: 15984982
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg neostigmine
Trial: 15984982
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg neostigmine + 0.4 mg glycopyrrolate
Trial: 7474041
Drug: 6.9% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9% carbohydrate-electrolyte solution (CHO)
Trial: 1849786
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cisplatin at 70 mg/m2 i.v. on day 1 and etoposide at 100 mg/m2 i.v. on day 1 and 200 mg/m2 orally on days 2 and 3)
Trial: 6891844
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cisplatin
Trial: 6891844
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of different cytostatic drugs
Trial: 6891844
Drug: Modern chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern chemotherapy with cisplatin
Trial: 28054322
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g/d for 5 days)
Trial: 20488830
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g glucose
Trial: 20122586
Drug: Landiolol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.125 mg/kg loading infusion followed by 0.04 mg/kg/min infusion)
Trial: 17717930
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with magnesium sulfate
Trial: 14586719
Drug: Losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (25 to 100 mg/day)
Trial: 14586719
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 5 mg/day)
Trial: 10776007
Drug: 100-mg slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg slow-release aspirin (Disprin CV) daily
Trial: 8924063
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg twice daily
Trial: 1579511
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Trial: 1579511
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Trial: 22847373
Drug: Thiopental plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental plus ketamine (0.5 mg/kg)
Trial: 16148375
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus enalapril (10‐20 mg/day)
Trial: 16148375
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus Accupro (slow titration from 5 to a maximum 20 mg/day)
Trial: 16148375
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (glycosides, diuretics, peripheral vasodilators)
Trial: 26197707
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg/day
Trial: 12115175
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 800 mg/day
Trial: 12115175
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 1200 mg/day
Trial: 10471564
Drug: Heparin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (10 U/ml)
Trial: 10471564
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and Vancomycin (10 U/ml and 25 microg/ml)
Trial: 2291418
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc supplementation (45-90 mg of Zn2+, as zinc sulfate)
Trial: 7317899
Drug: Nifedipine 0
RxNorm normalized name: nifedipine 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 0 mg
Trial: 31504721
Drug: High-sodium, high-cheese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium, high-cheese intervention (HNaC; 5500 mg/d sodium, 170 g/d cheese)
Trial: 31504721
Drug: Low-sodium, high-cheese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium, high-cheese intervention (LNaC; 1500 mg/d sodium, 170 g/d cheese)
Trial: 31504721
Drug: High-sodium, no-dairy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium, no-dairy intervention (HNa; 5500 mg/d sodium)
Trial: 11274545
Drug: MS-325 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-325 (all doses)
Trial: 11274545
Drug: Conventional contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional contrast agent-enhanced angiography
Trial: 2463702
Drug: Stable epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable epidural opioid treatment (median dose: 90 mg morphine/24 hours, range 16‐600)
Trial: 2463702
Drug: Stable epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable epidural opioid treatment
Trial: 2463702
Drug: Epidural opioid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural opioid treatment of neurogenic pain
Trial: 2463702
Drug: Epidural opioid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural opioid treatment in low dosage group (less than 300 mg morphine/24 hours)
Trial: 2463702
Drug: Epidural opioid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural opioid treatment in high dosage group (equal or greater than 300 mg morphine/24 hours)
Trial: 229506
Drug: ACTH-fragment 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH-fragment 4-10 (30 mg SC)
Trial: 31099281
Drug: Xiaoaiping (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoaiping (combined with routine chemotherapy)
Trial: 31099281
Drug: Routine chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine chemotherapy only (control group)
Trial: 12781509
Drug: Antibiotics to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics to reduce the reservoir of infection
Trial: 8963479
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril (ramiprilat)
Trial: 6261369
Drug: Veralipride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veralipride (100 mg/day for 20 days)
Trial: 30179573
Drug: 20-week dialectical
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-week dialectical behavior therapy (DBT) skills training group
Trial: 30497507
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of phytosterols and 10 g/day of inulin-enriched soymilk
Trial: 22960644
Drug: Active monochromatic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active monochromatic infrared energy (MIRE) therapy
Trial: 22960644
Drug: Placebo MIRE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MIRE therapy
Trial: 18821708
Drug: Glucosamine 500
RxNorm normalized name: glucosamine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine 500 mg 3 times daily
Trial: 18821708
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate 400 mg 3 times daily
Trial: 12388930
Drug: Colostrinin® (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrinin® (100 μg of PRP complex) taken every other day for three weeks, followed by a 2-week hiatus, for a total of 16 months (or 28 months for 13 patients).
Trial: 12388930
Drug: Colostrinin® (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrinin® (100 μg of PRP complex)
Trial: 1971540
Drug: beta 1-blockade
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta 1-blockade (atenolol, 50 mg, administered two times)
Trial: 1971540
Drug: beta 2-blockade
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta 2-blockade (ICI 118,551, 50 mg, administered three times)
Trial: 7026038
Drug: Heparin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1,000 units/ml) injected intraarterially at a dosage of 0.1 mg/kg prior to catheter removal
Trial: 7026038
Drug: Placebo injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected intraarterially at a dosage of 0.1 mg/kg prior to catheter removal
Trial: 7026038
Drug: Heparin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1,000 units/ml)
Trial: 30601417
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg 1 day before surgery and for 6 weeks after surgery)
Trial: 22710021
Drug: High-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose statin
Trial: 21464051
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no statin/low-dose statin)
Trial: 18832244
Drug: Maraviroc once
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc once daily
Trial: 18832244
Drug: Maraviroc twice
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc twice daily
Trial: 16750963
Drug: Regular non-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular non-aspirin NSAID use
Trial: 1536472
Drug: Pentoxifylline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (2 x 600 mg oral per day)
Trial: 23638711
Drug: Prenatal 60
RxNorm normalized name: ARDISIA CRENATA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal 60 mg iron and folate combined with UHM
Trial: 20702514
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy for 20 weeks
Trial: 20702514
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment with disconnected magnetotherapy equipment for 20 weeks
Trial: 30986791
Drug: RotaTeq vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq vaccine
Trial: 17117100
Drug: Topical betacaine
RxNorm normalized name: Butacaine
DrugBank: Butacaine (DB11502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betacaine application
Trial: 17117100
Drug: Topical betacaine
RxNorm normalized name: Butacaine
DrugBank: Butacaine (DB11502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betacaine followed by skin cooling
Trial: 15265098
Drug: Helping during
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Helping during treatment
Trial: 11933878
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of steroids (oral or intramuscular dexamethasone, 0.6 mg/kg)
Trial: 11933878
Drug: Steroids in
RxNorm normalized name: Other antiinflammatory and antirheumatic agents, non-steroids in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids in pharyngitis
Trial: 11933878
Drug: Single-dose and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose and short-term steroid therapy (less than a week)
Trial: 11933878
Drug: Routine use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine use of steroids for recurrent ENT infections
Trial: 9640129
Drug: Sulphasalazine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine therapy
Trial: 1093427
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 10 mg diazepam
Trial: 1093427
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection into the thigh of 10 mg diazepam
Trial: 1093427
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection into the buttock of 10 mg diazepam
Trial: 1093427
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and thigh routes of administration
Trial: 27992949
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing for phenprocoumon in younger patients (< 75 years)
Trial: 27992949
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing for phenprocoumon in older patients (≥ 75 years)
Trial: 27992949
Drug: Acenocoumarol users
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol users with genotype-guided dosing
Trial: 25971907
Drug: Obatoclax (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax (20 mg/m2) in combination with fludarabine and rituximab (FR)
Trial: 17658633
Drug: Bosentan (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.)
Trial: 17053955
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for 8 weeks
Trial: 14689888
Drug: DBTC catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBTC catheter (transurethral perfusion and drainage with antibiotics)
Trial: 6143042
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50, intranasally)
Trial: 6143042
Drug: Inactivated vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccine (administered intramuscularly)
Trial: 6143042
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50)
Trial: 6143042
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated cold‐adapted reassortant influenza virus vaccine
Trial: 27752167
Drug: CHOPE+L-asparaginase (L-ASP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOPE+L-asparaginase (L-ASP) regimen
Trial: 27752167
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival rates in CHOPE+L
Trial: 22041866
Drug: mIL‐11 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mIL‐11 (7.5 μg/kg/day) for 10 days, beginning 72 h after chemotherapy (cycle-1)
Trial: 22041866
Drug: rhIL‐11 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL‐11 (25 μg/kg/day) for 10 days (cycle-2)
Trial: 20215823
Drug: Antibiotics (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (Group 1)
Trial: 20215823
Drug: EPS-Antibiotics (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPS-Antibiotics (Group 4)
Trial: 17661724
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Aurene, 600 mg)
Trial: 17661724
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Trileptal, 600 mg)
Trial: 16160416
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Trial: 16160416
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Trial: 16160416
Drug: 0.8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Trial: 1824143
Drug: Sucralfate, 1
RxNorm normalized name: Sucralfate, 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, 1 g 4 times a day (Group 1)
Trial: 1824143
Drug: Famotidine, 40
RxNorm normalized name: Famotidine, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine, 40 mg single evening dose (Group 2)
Trial: 6242957
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg bid
Trial: 29601316
Drug: Diazoxide (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (200-400 mg daily, twice a day)
Trial: 25771490
Drug: Capsaicin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (5 mg/d)
Trial: 24725805
Drug: Oral α‐methyl‐para‐tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral α‐methyl‐para‐tyrosine (AMPT)
Trial: 22295812
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of acupuncture and medicine (heat-producing needling at Pishu (BL 20) and Zhishi (BL 52) with Terazosin Hydrochloride, Bisoprolol Fumarate tablets, or compound Reserpinum Triamterene tablet for high blood pressure)
Trial: 22295812
Drug: Medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine group I (Renin‐Angiotensin‐Aldosterone system interruption with Benazepril Hydrochloride and Telmisartan for blood pressure control)
Trial: 22295812
Drug: Medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine group II (placebo with same medicine therapy as combined therapy for high blood pressure)
Trial: 17703390
Drug: Sedato-analgesic cocktail
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedato-analgesic cocktail (midazolam, ketamine, pentazocine plus propofol) (Group B)
Trial: 12394941
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of human serum albumin every 8 hrs with continuous infusion furosemide
Trial: 10337446
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort extract LoHyp-57 (800 mg daily)
Trial: 1780996
Drug: Ivermectin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (100 micrograms/kg, single dose)